Targeting cancer metastasis with antibody therapeutics. (18th January 2021)

• Record Type: Journal Article
• Authors: Yang, Huilin; Kuo, Yun‐Huai; Smith, Zion I.; Spangler, Jamie
• Is Part Of: Wiley interdisciplinary reviews. Volume 13:Number 4(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-01-18
• Subjects: antibody -- cancer -- cell migration -- metastasis -- therapeutic; Nanomedicine -- Periodicals; Nanotechnology -- Periodicals; Biotechnology -- Periodicals; Ultrastructure (Biology) -- Periodicals; 610.28
• DOI: 10.1002/wnan.1698
• Languages: English
• ISSNs: 1939-5116

Abstract

Abstract: Cancer metastasis, the spread of disease from a primary to a distal site through the circulatory or lymphatic systems, accounts for over 90% of all cancer related deaths. Despite significant progress in the field of cancer therapy in recent years, mortality rates remain dramatically higher for patients with metastatic disease versus those with local or regional disease. Although there is clearly an urgent need to develop drugs that inhibit cancer spread, the overwhelming majority of anticancer therapies that have been developed to date are designed to inhibit tumor growth but fail to address the key stages of the metastatic process: invasion, intravasation, circulation, extravasation, and colonization. There is growing interest in engineering targeted therapeutics, such as antibody drugs, that inhibit various steps in the metastatic cascade. We present an overview of antibody therapeutic approaches, both in the pipeline and in the clinic, that disrupt the essential mechanisms that underlie cancer metastasis. These therapies include classes of antibodies that indirectly target metastasis, including anti‐integrin, anticadherin, and immune checkpoint blocking antibodies, as well as monoclonal and bispecific antibodies that are specifically designed to interrupt disease dissemination. Although few antimetastatic antibodies have achieved clinical success to date, there are many promising candidates in various stages of development, and novel targets and approaches are constantly emerging. Collectively, these efforts will enrich our understanding of the molecular drivers of metastasis, and the new strategies that arise promise to have a profound impact on the future of cancer therapeutic development. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Abstract : Tumor metastasis, which is responsible for over 90% of all cancer deaths, can be broadly categorized into five stages: invasion, intravasation, circulation, extravasation, and colonization. Antibody therapeutics have been developed that either indirectly or directly target various stages of the metastatic process.